There are currently 948 ongoing clinical trials involving Ovarian Cancer
Of the 948 trials,278 trials are in Phase I
Furthermore, 278 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Ovarian Cancer, an oncology condition. The largest number of ongoing clinical trials for Ovarian Cancer is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Ovarian Cancer-related drug trials.
National Cancer Institute US: The leading ongoing Ovarian Cancer related clinical trial sponsor
National Cancer Institute US is the top sponsor for Ovarian Cancer-related ongoing clinical trials.
University of Texas MD Anderson Cancer Center, AstraZeneca Plc, Pfizer Inc, and University Health Network are among other notable clinical trial sponsors involved in Ovarian Cancer. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Ovarian Cancer
Olaparib (Lynparza), Bevacizumab biosimilar (Mvasi), and Niraparib (MK-4827, Zejula) are among the key marketed drugs involving Ovarian Cancer.
Niraparib (MK-4827, Zejula) is an anti-neoplastic agent. It functions viaPoly [ADP Ribose] Polymerase 1 (ADP Ribosyltransferase Diphtheria Toxin Like 1 or NAD(+) ADP Ribosyltransferase 1 or Poly[ADP Ribose] Synthase 1 or PARP1 or EC 2.4.2.30) Inhibitor; Poly [ADP Ribose] Polymerase 2 (ADP Ribosyltransferase Diphtheria Toxin Like 2 or NAD(+) ADP Ribosyltransferase 2 or Poly[ADP Ribose] Synthase 2 or PARP2 or EC 2.4.2.30) Inhibitor mechanism of action. Niraparib is marketed for the treatment of Ovarian Cancer and several other indications including Fallopian Tube Cancer, Epithelial Ovarian Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), and Metastatic Adenocarcinoma of The Pancreas. Niraparib was first approved in 2017 and is marketed globally including the US, the UK, France, Germany, China, and Japan by several pharma giants including AstraZeneca Pharmaceuticals LP, Organon Pharma (UK) Ltd, and GlaxoSmithKline Plc.
Bevacizumab biosimilar (Mvasi) is a recombinant humanized monoclonal IgG1 antibody. It functions via Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor mechanism of action. It is formulated as solution and solution concentrate for intravenous route of administration. Bevacizumab biosimilar is marketed for the treatment of Ovarian Cancer and several other indications including Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Colorectal Cancer, Cervical Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma. Bevacizumab biosimilar was first approved in 2017 and is marketed globally including the US, France, Germany, the UK, and Japan by Amgen Inc and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward